Peptide Research Ethics in the UAE: MOHAP IRB Framework, Informed Consent & Where to Buy Research Peptides (Dubai 24h Delivery, 2026)

Why UAE Peptide Researchers Need an Ethics Map

Peptide procurement in the UAE has matured faster than the ethics literacy around it. A typical 2026 enquiry from a Dubai clinic, Sharjah university lab or Abu Dhabi performance-medicine practice looks like this: "We want to study Retatrutide tolerability in a small cohort — can you ship and what do we need on the paperwork side?" Two completely different answers apply, depending on whether the cohort is cell lines and analytical samples, or living human volunteers.

This guide maps the UAE research-ethics framework as it stands in mid-2026 — the MOHAP Federal Research Ethics Guidelines, the Dubai Health Authority (DHA) IRB pathway, the Department of Health Abu Dhabi (DoH) Research Governance Framework, and the federal Medical Products Law (Federal Law No. 7 of 2019). It then explains where REVIVE LAB fits — as a research-chemical supplier shipping Retatrutide, Tesamorelin, GHK-Cu and others with 24h same-day delivery from Dubai stock — and where the legal line sits between supplying a research-use vial and using it on a human subject.

The Two-Track Model: Research-Use vs Human-Subject Research

The single most useful concept for any UAE peptide investigator is the two-track model. Confusing the two is the source of almost every avoidable regulatory problem.

REVIVE LAB operates entirely on the left-hand column. Every vial shipped — Retatrutide 5 mg, Retatrutide 10 mg, Tesamorelin 5/10 mg, GHK-Cu 50/100 mg, BPC-157 5 mg, TB-500 5 mg, MOTS-c 10 mg, Semax 10 mg, NAD+ 100 mg, Bacteriostatic Water 3 mL — leaves Dubai with an HPLC certificate of analysis and a research-use-only label. The right-hand column is the principal investigator's responsibility.

MOHAP, DHA and DoH: Who Approves What

The UAE runs a federal-plus-emirate model for health research governance. The federal Ministry of Health and Prevention (MOHAP) issues the umbrella Research Ethics Guidelines and oversees RECs in MOHAP-administered facilities (Northern Emirates, federal hospitals). Dubai and Abu Dhabi each run their own parallel systems because of their independent health authorities.

MOHAP Research Ethics Committee (federal)

• Jurisdiction: federal MOHAP hospitals, Northern Emirates facilities, multi-emirate studies
• Authority: MOHAP Federal Law No. 7 of 2019 on Medical Products + MOHAP REC Guidelines
• Typical timeline: 6–12 weeks from full submission
• Required: protocol, investigator's brochure, bilingual consent, CVs, insurance certificate

DHA IRB — Dubai Scientific Research Ethics Committee (DSREC)

• Jurisdiction: any human-subject research conducted in Dubai (DHA, free zones including DHCC, private clinics)
• Pathway: DSREC online portal, fee-based review
• Note: Dubai Healthcare City has its own additional MBRU-IRB layer for studies in DHCC facilities

DoH Abu Dhabi — Research Governance Framework

• Jurisdiction: Abu Dhabi emirate (SEHA, Cleveland Clinic AD, M42 network)
• Pathway: DoH Research Governance portal + institutional IRB (e.g., CCAD IRB, SEHA IRB, KKWH IRB)
• Distinctive: requires Abu Dhabi Health Data Standards compliance for any data export

Informed Consent: What UAE IRBs Actually Require

If your protocol crosses into human-subject territory — even informally, even just "we'll measure HbA1c on three willing colleagues" — the consent document is non-negotiable. UAE RECs apply the Declaration of Helsinki standard as adapted by MOHAP, with specific local additions:

1. Bilingual Arabic + English. Both versions must be on file. Arabic is the binding language in any dispute.
2. Plain-language description of the peptide, dose, route, frequency, and expected duration.
3. Honest risk disclosure — for GLP-1/GIP/glucagon agonists like Retatrutide, this includes the 6–8 bpm heart-rate elevation Jastreboff 2023 documented, GI symptoms, and the gallbladder/pancreatitis signals from the broader GLP-1 class.
4. Statement that the compound is not a registered UAE medicinal product and is being used under a research protocol.
5. Right to withdraw at any time without penalty.
6. Data handling per UAE PDPL (Federal Decree-Law No. 45 of 2021) and Abu Dhabi/Dubai health-data residency rules.
7. Insurance & indemnity — who pays if something goes wrong, named carrier on file.
8. Investigator and REC contact details for complaints.

UAE Delivery & Sourcing — Where to Buy Research Peptides with 24h Delivery

For the research-use side of the equation — analytical work, in-vitro studies, validated reference standards — REVIVE LAB is the fastest UAE-resident source. Buy research peptides UAE with 24h delivery directly from Dubai stock, no customs delay, no cross-border cold-chain risk.

Delivery windows by emirate (2026)

What ships from Dubai stock today

• Retatrutide 5 mg & 10 mg — in stock UAE, 24h delivery Dubai/Abu Dhabi/Sharjah
• Tesamorelin 5 mg & 10 mg — same-day Dubai dispatch
• GHK-Cu 50 mg & 100 mg — copper-peptide research vials, cold-chain
• BPC-157 5 mg, TB-500 5 mg, MOTS-c 10 mg, Semax 10 mg, NAD+ 100 mg
• Bacteriostatic Water 3 mL for reconstitution

Cold-chain is preserved end-to-end. Vials leave the Dubai facility in insulated boxes with cold packs sized to the route — overnight to Northern Emirates uses double-pack insulation. Each shipment carries a per-batch HPLC certificate of analysis showing purity, mass-spec confirmation of sequence, and bacterial endotoxin limits.

Research-Use Products: What That Label Actually Means

The phrase "research use only" carries real legal weight in the UAE. It means the vial is a laboratory reagent, sold to the buyer for in-vitro experimentation, analytical reference, or animal protocols inside a licensed facility. It is not a finished pharmaceutical product, has not been registered with MOHAP for human use, and the supplier — REVIVE LAB in this case — does not represent it as safe or appropriate for human administration.

This is the same legal posture that governs research-chemical suppliers worldwide. The buyer assumes responsibility for what the compound is used for after delivery. If a buyer chooses to extrapolate to human subjects, they must — independently — obtain MOHAP/DHA/DoH IRB approval, file the appropriate Clinical Trial Application if the compound is unregistered, and document informed consent.

The Common Failure Modes (and How to Avoid Them)

Failure 1: Treating "small studies" as exempt

UAE RECs do not have a meaningful "minimal-risk exemption" for unregistered compounds. A three-volunteer pilot of an unregistered peptide still requires REC review. The Belmont-style minimal-risk shortcut common in US academic IRBs does not map cleanly to MOHAP rules.

Failure 2: Verbal consent

Verbal consent is not accepted for any peptide protocol. Signed bilingual documentation is the floor.

Failure 3: Importing without HPLC documentation

Buying from non-UAE suppliers introduces customs risk, cold-chain breaks, and missing certificates of analysis. Sourcing locally from REVIVE LAB UAE — buy research peptides 24h delivery eliminates all three.

Failure 4: Mixing research-use stock with clinical stock

If a licensed clinic also runs research, the research vials must be physically segregated and labelled. Co-mingling is a flag in any DHA inspection.

Failure 5: Skipping the data-protection layer

Federal Decree-Law No. 45 of 2021 (UAE PDPL) plus the Abu Dhabi Health Information & Cyber Security Standard apply to any research data. RECs increasingly ask for a data-protection impact assessment alongside the protocol.

How REVIVE LAB Supports the Research Side

• HPLC certificates of analysis on every batch — required documentation for any analytical method paper
• Mass-spec confirmation of peptide sequence on file, available on request for IRB submissions that reference the supplier
• Cold-chain shipping from Dubai stock — 24h same-day to Dubai, next-day to Abu Dhabi and Sharjah
• Consistent batch sourcing so longitudinal protocols don't see vial-to-vial drift
• Bacteriostatic Water 3 mL available alongside lyophilised vials
• Research-use-only labelling that satisfies UAE customs and any institutional biosafety officer's documentation requirement

For protocol-design questions specific to each compound, see our deeper guides: retatrutide titration schedule, tesamorelin IGF-1 monitoring, and GHK-Cu topical vs injection.

Practical Checklist Before You Start a UAE Peptide Study

1. Decide track: in-vitro/research-use vs human-subject. If unsure, default to human-subject.
2. If human-subject: identify the correct IRB (MOHAP REC, DSREC, DoH, DHCC MBRU-IRB).
3. Write the protocol with explicit dose, route, frequency, primary/secondary endpoints, stopping rules.
4. Draft bilingual consent — Arabic + English, signed.
5. Secure indemnity insurance naming the protocol.
6. Submit Clinical Trial Application if compound is unregistered.
7. Order research stock from REVIVE LAB UAE — 24h delivery to Dubai, Abu Dhabi, Sharjah, in stock.
8. Document chain of custody from delivery through use.
9. Maintain PDPL-compliant data storage.
10. Report adverse events to the REC and (if applicable) MOHAP Pharmacovigilance.